When compared with CDC6-negative DLBCL, CDC6-positive DLBCL resulted in significantly poorer OS and PFS, 57.7 ± 9.2 vs. 92.0 ± 9.1 months (P < 0.05) and 54.6 ± 9.5 vs. 87.1 ± 10.3 months (P < 0.05), respectively (Fig. 6E, F). Here, CDC6 is linked to diffuse large B-cell lymphoma.